Home  / Global / Healthcare Register for Membership

IRW-Press: Sirona Biochem Announces Successful Synthesis Of Anti-Inflammatory Compound For Bloom Burton & Co. Joint Venture

Published on 31 July 2014

Discover the World Of Judaica

by Press Office

(IRW-PRESS and WireNews)

Vienna, Austria

Sirona Biochem Corp. (TSX-V: SBM, OTCQX: SRBCF, FSE: ZSB), (the “Company”) announces the achievement of the first batch of compound in the joint venture with Bloom Burton & Co. (“Bloom Burton”) Compounds developed within the framework of the JV will be entering development in the areas of rare inflammatory and infectious diseases.

At present, there are unmet market needs in the areas of rare or neglected inflammatory diseases and bacterial resistance. Sirona and Bloom Burton are identifying and designing a library of compounds to address these substantial markets which combined reach nearly $2 Billion US each year globally. Sirona is responsible for the chemistry and Bloom Burton for the financing, clinical validation as well as the commercialization of the compounds.

“We could not be more pleased with the completion of the first synthetic compounds. This is a major milestone in the development of our portfolio for rare and neglected diseases” said Howard Verrico, CEO of Sirona Biochem. “The team at Bloom Burton will plan for the testing of our new anti-inflammatory compounds in the near future. In the next several months, we will be working on the development of further compounds for our JV with Bloom Burton as planned.”

About Bloom Burton & Co.

Bloom Burton & Co. exists to accelerate monetization in healthcare. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deeper level of diligence, which combined with a creative and entrepreneurial culture, leads to the right monetizing events for companies and investors. Bloom Burton’s many services include capital raising, mergers and acquisitions advisory, equity research, scientific and medical consulting, direct investing, company creation and incubation. For more information, please visit http://www.bloomburton.com.

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit http://www.sironabiochem.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information regarding this press release, contact:

Christopher Hopton, CFO

Sirona Biochem Corp.

Phone: 1.604.282.6064

Email: chopton@sironabiochem.com

Sirona Biochem Corp.

605-889 West Pender Street, Vancouver, BC, Canada, V6C 3B2

T 604.641.4466

F 604.608.5471

TF 1.888.SIRONA1 (7476621)



Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.


  • Joachim Brunner
  • IRW-Press
  • PR Contact
  • Tel: +43724221193011
Enter your email:
Enter Subject:
Enter your message:
Please enter this numbers in the fields:
  Click image to get a new code.
Enter code:

Posted 2014-07-31 08:57:00